New drug combo offers hope for tough head and neck cancers
NCT ID NCT07546383
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two antibodies (iparomlimab and tuvonralimab) given together, with or without chemotherapy, for people with advanced head and neck cancer that has come back or spread after at least one prior treatment. The goal is to see if the combination can shrink tumors and control the disease. About 32 adults aged 18 to 75 will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Hainan Medical University
RECRUITINGHaikou, Hainan, 570311, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smartphone app aims to combat malnutrition in head and neck cancer patients
- Can adding radiation boost immunotherapy against spread head and neck cancer?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- New hope for hard-to-treat cancers? experimental combo enters phase 2 trial
- New antibody drug aims to unleash immune system on Hard-to-Treat cancers
- Could fewer radiation sessions after surgery improve quality of life for head and neck cancer patients?